Skip to main content
Log in

Exemestan als Chemoprävention des Mammakarzinoms bei postmenopausalen Frauen

Exemestan for breast cancer prevention

  • Journal Club
  • Published:
Der Onkologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Literatur

  1. Cuzick J, Powles T, Veronesi U et al (2003) Overview of the main outcomes in breast-cancer prevention trials. Lancet 361:296–300

    Article  PubMed  CAS  Google Scholar 

  2. Fisher B, Costantino JP, Wickerham DL et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371–1388

    Article  PubMed  CAS  Google Scholar 

  3. Freedman AN, Yu B, Gail MH et al (2011) Benefit/risk assessment for breast cancer chemoprevention with raloxifen or tamoxifen for women age 50 yrs or older. J Clin Oncol (Epub adead of print)

  4. Visvanthan K, Chlebowski RT, Hurley P et al (2009) American Society of Clinical Oncology clinical practice guiedeline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 27:3235–3258

    Article  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to C. Richter-Ehrenstein.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Richter-Ehrenstein, C. Exemestan als Chemoprävention des Mammakarzinoms bei postmenopausalen Frauen. Onkologe 17, 834–836 (2011). https://doi.org/10.1007/s00761-011-2116-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-011-2116-7

Navigation